Metvixia and Aktilite CL128 approved by FDA
The supplement to the NDA for Metvixia (Metvixia(TM) is the US trade name) submitted 28 June 2007, comprised documentation on the new medical device Aktilite CL128 developed by Photocure as well as data from two new pivotal and three supportive phase 3 studies to document the efficacy of Metvixia in combination with Aktilite CL 128. In the pivotal studies 211 patients with multiple AKs in face or scalp were treated with Metvixia Cream or placebo prior to illumination with Aktilite. Both studies showed significantly better response with Metvixia compared to placebo at 3 months after treatment. The results confirmed the excellent results seen in earlier phase 3 studies with Metvixia photodynamic therapy (PDT).
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.